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At a Glance Commentary. 58 
Scientific Knowledge on the Subject: Pseudomonas aeruginosa is the dominant airways 59 
infection in people with cystic fibrosis (CF). People can harbor genetically indistinguishable 60 
strains of P. aeruginosa, which suggests that cross infection may be an important mode of 61 
transmission, although the mechanisms are not well understand. Droplet nuclei containing P. 62 
 
 
aeruginosa produced during coughing can remain viable for extended periods, raising the 63 
possibility of airborne transmission. The CF Foundation recommends that people with CF 64 
wear a surgical mask in communal areas to reduce pathogen acquisition and transmission. 65 
What This Study Adds to the Field: This comparative observational study demonstrated 66 
that surgical masks and the N95 masks are effective in reducing aerosols containing viable P. 67 
aeruginosa 2-metres from source during coughing in people with CF. Short-term use of face 68 
masks was well tolerated in people with CF lung disease, with the surgical mask rated more 69 
comfortable than the N95 mask. Cough etiquette reduced viable aerosols to a lesser extent 70 
than face masks. 71 
 72 
This article has an online data supplement, which is accessible from this issue's table of 73 
content online at www.atsjournals.org 74 
 75 
76 
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ABSTRACT   77 
Rationale: People with cystic fibrosis (CF) generate Pseudomonas aeruginosa in droplet 78 
nuclei during coughing. The use of surgical masks has been recommended in healthcare 79 
settings to minimise pathogen transmission between CF patients.  80 
Objective: To determine if face masks and cough etiquette reduce viable P. aeruginosa 81 
aerosolised during cough.   82 
Methods: Twenty-five adults with CF and chronic P. aeruginosa infection were recruited. 83 
Participants performed six talking and coughing maneuvers, with or without face masks 84 
(surgical and N95) and hand covering the mouth when coughing (cough etiquette) in an 85 
aerosol-sampling device. An Andersen Impactor sampled the aerosol at 2-meters from each 86 
participant. Quantitative sputum and aerosol bacterial cultures were performed and 87 
participants rated the mask comfort levels during the cough maneuvers. 88 
Measurements and Main Results: During uncovered coughing (reference maneuver), 19/25 89 
(76%) participants produced aerosols containing P. aeruginosa, with a positive correlation 90 
found between sputum P. aeruginosa concentration (CFU/mL) and aerosol P. aeruginosa 91 
CFUs. There was a reduction in aerosol P. aeruginosa load during coughing with surgical 92 
mask, coughing with N95 mask and cough etiquette compared with uncovered coughing 93 
(p<0.001). A similar reduction in total CFUs was observed for both masks during coughing, 94 
yet participants rated surgical masks more comfortable (p=0.013). Cough etiquette provided 95 
approximately half the reduction of viable aerosols of the mask interventions during 96 
voluntary cough. Talking was a low viable aerosol producing activity. 97 
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Conclusions: Face masks reduce cough generated P. aeruginosa aerosols, with the surgical 98 
mask providing enhanced comfort. Cough etiquette was less effective at reducing viable 99 
aerosols.  100 
Word count = 248 101 
Key words: cystic fibrosis; infection control; surgical mask, N95 mask; cough etiquette 102 
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INTRODUCTION  117 
Pseudomonas aeruginosa is the dominant pathogen in the airways of people with cystic 118 
fibrosis (CF), with a prevalence of up to 70% in adults (1-3). Chronic P. aeruginosa infection 119 
is associated with pulmonary function decline, increased exacerbations, poorer health-related 120 
quality of life and reduced survival (4-6). Studies have demonstrated that unrelated people 121 
with CF can harbor genetically indistinguishable strains, suggesting person-to-person spread 122 
of P. aeruginosa (7-11). Consequently, CF infection control guidelines published in 2003 123 
sought to minimise potential contact and droplet transmission of pathogens and 124 
recommended cohort segregation according to microbiological status, single room inpatient 125 
accommodation and a separation distance of 1-meter between people with CF (12). Although 126 
such measures are thought to have contributed to a reduction in epidemic P. aeruginosa      127 
(13) and Burkholderia cenocepacia strain acquisition (14), cross infection with CF pathogens 128 
has continued (11, 15, 16). 129 
Airborne transmission of P. aeruginosa was first suggested as a possible mode of cross-130 
infection by studies that assessed environmental air contamination in CF clinical care settings 131 
(17) and cough aerosols from people with CF (18). Particle size diameter is used to categorize 132 
respiratory aerosols into droplets (>5µm) and droplet nuclei (≤5µm); with the latter a 133 
consequence of droplet evaporation and capable of airborne transmission (19). Our earlier 134 
work demonstrated that cough generated droplet nuclei containing P. aeruginosa in the 135 
respirable size range remained viable for up to 45-minutes and were detected up to 4-meters 136 
from the source (20). The updated CF infection control guidelines published in 2014 137 
recommended a separation distance of 2-meters and included the specific recommendation 138 
for people with CF to wear a surgical mask in communal areas of healthcare facilities (21). 139 
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Face masks and cough etiquette (i.e. coughing into the hand or arm) are strategies that may 140 
interrupt aerosol dispersal. The primary role of the surgical mask is to prevent contamination 141 
of the environment by infectious droplets. The relatively low efficiency capture of aerosols, 142 
particularly during cough, and incomplete seal may allow particles to escape around the 143 
perimeter (22). The N95 mask provides inward protection from inhaled airborne pathogens, 144 
and it is reasonable to also expect limitation of aerosolised infectious material generated by 145 
the wearer. To date there is limited evidence of outward protection by surgical and N95 146 
masks and the tolerability of these interventions has not been widely studied in patients with 147 
lung disease. Therefore, this study aimed to determine and compare the effectiveness and 148 
comfort of two commonly utilized face masks and cough etiquette on dispersal of aerosolised 149 
P. aeruginosa during talking and coughing in adults with CF. Some of the results of this 150 
study have been previously reported in the form of an abstract (23).  151 
 152 
METHODS  153 
See online supplement for additional details.   154 
Participants: Participants (n=25) were recruited from The Prince Charles Hospital (TPCH) 155 
Adult Cystic Fibrosis Centre (ACFC), Brisbane, Australia in 2015. Eligible participants had a 156 
confirmed CF diagnosis, aged >18 years and chronic P. aeruginosa infection as determined 157 
by modified Leed’s criteria (3). Exclusion criteria comprised recent haemoptysis (>50ml), 158 
pneumothorax, pregnancy and cough syncope. Written, informed participant consent was 159 
obtained and the study was approved by the local ethics committee.  160 
Aerosol sampling system: Using a validated, closed wind-tunnel system, viable aerosols 161 
were collected at 2-meters from participants (24); the sampling distance was defined in 162 
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accordance with the current US CFF Infection Prevention and Control Guidelines 163 
recommending 2-meters between-person separation (21). Seated participants positioned their 164 
head within the tunnel with a weighted material cover rested over the shoulders and a slight 165 
positive tunnel pressure to prevent room air contamination (20).  166 
Aerosol sampling protocol: Participants completed six maneuvers on a single day: 1) 167 
talking; 2) talking wearing a tied surgical mask (Kimberley-Clark TECNOL Fluidshield Fog-168 
Free Surgical Mask, Georgia, USA); 3) uncovered coughing (reference maneuver); 4) 169 
coughing wearing a tied surgical mask; 5) coughing wearing an N95 mask (Kimberley-Clark 170 
N95 Particulate Filter Respirator, NSW, Australia); 6) coughing with their hand covering 171 
their mouth (cough etiquette). The testing order of the uncovered cough maneuver, coughing 172 
wearing a surgical mask and coughing wearing an N95 mask were randomized to minimize 173 
potential bias in aerosol production resulting from fatigue and airway clearance with repeated 174 
coughing (25). For logistical reasons, the cough etiquette test was the final maneuver 175 
performed and participants were asked to adopt their usual mouth covering technique (a 176 
glove was worn on the cough covering hand to minimize microbial dispersal from skin). 177 
Participants rested for ≥20 minutes between each maneuver. Face masks were sized and 178 
applied by a trained healthcare professional. 179 
Within the tunnel each participant completed 2-minutes of tidal breathing in high-efficiency 180 
particulate air (HEPA) filtered air to washout residual room air, then 5-minutes of the 181 
respective maneuver (talk/cough) during which aerosols were continuously sampled through 182 
a six-stage Andersen Impactor (Thermo Scientific™), followed by 2-minutes of tidal 183 
breathing. Participants then completed a 5-point comfort rating score (26) and provided 184 
comments regarding mask wear during coughing. Masks were weighed before and 185 
immediately after each maneuver. 186 
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Clinical Measurements: Demographic and clinical measurements were recorded, including: 187 
age, gender, body mass index (BMI) and intravenous antibiotic use in the week prior. A 188 
sputum sample was collected on the study day. Spirometry (FEV1 and FVC) was performed 189 
according to ATS/ERS standards (27) and the Global Lung Index (GLI) predicted scale (28) 190 
applied.  191 
Microbiology: Standardized qualitative and quantitative sputum cultures were performed, as 192 
previously described (20). P. aeruginosa identification was confirmed by oxidase testing, 193 
42°C growth and MALDI-TOF mass spectrometry. P. aeruginosa genotyping was 194 
undertaken using the Sequenom iPLEX20SNP assay, as previously described (29). 195 
Statistical analysis: A sample size calculation based on our earlier work (20) suggested 21 196 
patients were required to demonstrate a 40 percentage point reduction in the presence or 197 
absence of P. aeruginosa with 80% power with a two-tailed p=0.05. Therefore, 25 patients 198 
with CF and chronic P. aeruginosa were enrolled, allowing for 10-15% dropout to achieve a 199 
sample size of 21. SPSS version 22 was used for statistical analysis. Categorical variable 200 
associations were examined using Fisher’s Exact test. Continuous variables describing 201 
participant characteristics were examined using a Student t-test. Clinical and demographic 202 
variables were compared with the log transformed total P. aeruginosa aerosol colony forming 203 
units (CFUs) in the uncovered cough maneuver using a Pearson correlation test. The paired t-204 
test based on log transformed CFU was used to compare each intervention maneuver with the 205 
reference maneuver (uncovered coughing). Results were stratified by the level of aerosol 206 
production as follows: participants were classed as high, low or nil viable aerosol producers 207 
during the uncovered cough maneuver using an arbitrary pre-defined total CFU of ≥10 or 208 
<10, respectively, accumulated across the six-stages of the Andersen Impactor (Figure 1). 209 
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The Mann-Whitney U test was used to examine change in mask weight. McNemar’s test was 210 
used for matched pairs to compare comfort scores for the two mask types. 211 
 212 
RESULTS 213 
Participant overview: Twenty-five (15 male) adult participants with a mean (SD) age of 214 
31.3 (7.8) years, FEV1 50.7 (17.4) % predicted and BMI 22.1 (2.8) kg/m2 were recruited 215 
(Table 1).  Twenty-two (88%) participants were on maintenance azithromycin. Eleven (44%) 216 
participants were established on chronic inhaled antibiotic therapy (either continuous or 217 
cycling alternate month) and the remaining 14 (56%) participants had been prescribed inhaled 218 
antibiotic therapy (less frequently than alternate months) in the 12 months prior to the study.  219 
Eleven participants (44%) had received intravenous antibiotics in the week prior to their 220 
study involvement. The mean (SD) age, FEV1 % predicted and BMI of patients attending 221 
TPCH ACFC in 2015 was 30.7 (9.9) years, 66.7 (24.1) % predicted and 23.0 (4.2) kg/m2, 222 
respectively. In the preceding calendar year, of 282 patients reviewed at TPCH ACFC, 68.4% 223 
had chronic P. aeruginosa infection.  224 
Sputum microbiology: P. aeruginosa was cultured from the 24 sputum samples provided at 225 
a mean concentration of 6.3 x 107 CFU/mL (95% CI, 2.6 x 107 – 15.0 x 107; Table 1). 226 
Genotyping identified 12 different P. aeruginosa strains, including five common Australian 227 
shared strains (11); AUST-01 (n=6), AUST-02 (n=9), AUST-06 (n=6), AUST-07 (n=3), 228 
AUST-13 (n=1), five other minor shared strains, and two unique strains. Eight participants 229 
harbored more than one P. aeruginosa strain; two different strains were detected in seven 230 
participants, while one participant was infected with three major Australian shared strains 231 
(AUST-01, AUST-02 and AUST-06). Other CF pathogens identified in the sputum on the 232 
testing day comprised: Stenotrophomonas maltophilia (n=3), Aspergillus fumigatus (n=3), 233 
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Haemophilus influenzae (n=1) and Burkholderia cenocepacia (n=1). Five participants had a 234 
history of intermittent Staphylococcus aureus in the 12 months prior to the study but S. 235 
aureus was not isolated from sputum of participants on the day of testing.   236 
Aerosol sampling: 237 
Uncovered cough maneuver. Of the 25 participants, 19 (76%) produced aerosols containing 238 
viable P. aeruginosa in the uncovered cough maneuver at 2-meters (Table 2). The participant 239 
unable to produce a sputum sample, was one of the six who did not culture P. aeruginosa on 240 
the cough aerosol plates. Molecular typing revealed that for 16 individuals, the P. aeruginosa 241 
genotype(s) detected in the individual’s cough aerosols were genetically indistinguishable to 242 
those isolated in their matched sputum sample. Three other participants (two with one 243 
indistinguishable P. aeruginosa genotype in their matched aerosol/sputum combination; one 244 
with two indistinguishable P. aeruginosa strains in their matched aerosol/sputum 245 
combination) were each found to have one additional P. aeruginosa strain in their aerosol 246 
cultures that was not detected in their sputum. The three participants who had isolated S. 247 
maltophilia in their sputum also generated aerosols that grew this organism (confirmed by 248 
MALDI-TOF).  249 
When the total P. aeruginosa CFUs of uncovered cough aerosols was associated with 250 
demographic, clinical and microbiology parameters, a statistically significant correlation was 251 
identified only between log transformed sputum P. aeruginosa counts and total aerosol load 252 
(r=0.55, p=0.01). The mean (SD) percentage of culturable particles within the respirable size 253 
range (≤ 4.7µm, collected on Andersen stages 3 to 6) were 71% (27) in the uncovered cough 254 
maneuver and 86% (30) in the cough etiquette maneuver (p=0.21).   255 
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Talk maneuvers. No aerosol CFUs were recovered from either talk maneuvers for 23/24 256 
(96%) participants and a single aerosol P. aeruginosa CFU was cultured from the remaining 257 
two participants (one masked and one unmasked study; Table 2). 258 
Face masks and cough etiquette maneuvers. Of the 19 participants that produced culture 259 
positive aerosols during uncovered coughing, two (11%) produced P. aeruginosa positive 260 
aerosols wearing the surgical mask, and four (21%) grew P. aeruginosa in their aerosol 261 
cultures when wearing the N95 mask (Table 2). In contrast, 68% of these participants (n=13) 262 
grew P. aeruginosa in their aerosols using cough etiquette (Table 2).  263 
High viable aerosol production (total CFUs 10) was observed in 14/19 (74%) participants 264 
who cultured at least one CFU in the uncovered cough maneuver. In these participants a 265 
reduction in aerosol P. aeruginosa concentration (log CFU) was demonstrated with each 266 
strategy designed to interrupt aerosol dispersal: surgical mask (-94%); N95 mask (-94%); 267 
cough etiquette (-53%).  The surgical mask (p<0.001) and the N95 mask (p<0.001) were both 268 
effective in reducing infectious airborne dispersal compared to uncovered coughing, with 269 
cough etiquette providing less reduction in mean P. aeruginosa CFUs than both masks (Table 270 
3).  271 
Tolerability of the masks during cough maneuvers varied, with 13 (54%) participants 272 
providing a higher comfort rating to the surgical mask than the N95 mask, compared with 273 
two (8%) who provided a higher comfort rating to the N95 mask and nine (38%) who had no 274 
preference (p=0.013) (Table 4). Key comments regarding the masks by the participants 275 
included: a perceived restriction to or reduction in ease of breathing (n=15, [N95=12]), 276 
sensation of heat (n=9, [N95=6]), sensation of dampness (n=3, all surgical) and 277 
rubbing/pressure from the mask during coughing (n=2, [N95=1]). There was a similar change 278 
in weight of the surgical mask and the N95 mask (median (interquartile range) of 0.01 (0.00-279 
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0.02) grams and 0.02 (0.00-0.04) grams, respectively; p=0.23). Cough numbers for each 280 
maneuver were similar and there was no difference in the number of coughs during the N95 281 
mask (p=0.15) and cough etiquette (p=0.52) tests compared to the uncovered coughing 282 
intervention (Table S1), indicating that fatigue or participant motivation were unlikely to 283 
have impacted the accuracy of the maneuvers. 284 
Infection Control: P. aeruginosa or other CF pathogens were not cultured from blank 285 
aerosol tests or surface swabs of the tunnel. 286 
Adverse events: Overall, the maneuvers were well tolerated; however, one participant (listed 287 
for lung transplant and FEV1 32.5% predicted) discontinued the N95 mask study due to 288 
claustrophobia and increased dyspnoea after mask application.  289 
 290 
DISCUSSION 291 
This study demonstrates that at 2-meters from source, both surgical and N95 masks are 292 
highly effective in reducing aerosols containing viable P. aeruginosa in the droplet nuclei 293 
size range during voluntary coughing in people with CF. Our study uses a system that mimics 294 
a hospital environment and has several strengths; it was designed to reflect real-world 295 
occurrences by using a model that allows determination of air contamination at the 296 
recommended separation distance between people with CF and by investigating the effect of 297 
cough etiquette and two commonly available masks in hospitals on aerosol dispersal. The 298 
cough maneuvers examined may also closely replicate aerosol production during airway 299 
clearance sessions and spirometry procedures. Furthermore, we provide much-needed 300 
information on the short-term tolerability of mask wearing by persons with lung disease, 301 
which is an often-overlooked dimension of infection control.   302 
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Cross-infection between people with CF has increasingly been reported over the past two 303 
decades, initially with Burkholderia cepacia complex (30, 31), P. aeruginosa (9-11) and 304 
more recently Mycobacterium abscessus (15, 32). Progressive changes to infection control 305 
policies have been implemented including cohort segregation and changes to practice for 306 
patients with CF in the clinic and inpatient facility. Airborne transmission of CF pathogens in 307 
aerosol droplet nuclei has been suggested and such evidence has contributed to the enhanced 308 
rigor of these policies (17, 18). Increased separation distance between people with CF and the 309 
wearing of surgical masks during hospital visits are now recommended (21). Evidence to 310 
support the effectiveness of the latter strategy has been limited. Two previous studies 311 
evaluated the effect of surgical mask wearing on bioaerosol spread within a CF cohort. Our 312 
finding of a strong protective effect with surgical masks during cough maneuvers corroborate 313 
with and strengthen those of Driessche et al. who demonstrated an 86% reduction in 314 
environmental detection of airborne P. aeruginosa concentration during mask wearing 315 
compared to the reference (coughing without a surgical mask) in a controlled laboratory 316 
model (33). In contrast, Zuckerman and colleagues found no difference in rates of air 317 
contamination of outpatient exam rooms between mask wearing and unmasked patients with 318 
CF, although the overall positive air sample yield was low, including in the control group 319 
without mask (0.7%) (34).  320 
Three quarters of the participants that were studied produced aerosols containing viable P. 321 
aeruginosa at 2-meters during uncovered coughing. The only predictor of expired aerosol 322 
containing viable bacteria was the sputum load of P. aeruginosa, which agrees with the 323 
results of our earlier work (20), further suggesting burden of infection is a very important 324 
determinant of potential infectiousness. A previous study using artificially generated aerosols 325 
demonstrated that P. aeruginosa respiratory samples with a mucoid phenotype exhibited 326 
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improved survival, although this advantage did not extend to epidemic strains (35). The 327 
aerosol samples from the uncovered cough maneuvers in our study revealed both unique and 328 
shared Australian strains of P. aeruginosa, but the overall numbers were too small to make 329 
any conclusions regarding survival characteristics.  330 
To date, very few studies have directly compared the performance of various respiratory 331 
hygiene strategies in vivo and to our knowledge, this study is the first that investigates the 332 
outward protective effects of various interventions in a CF population with chronic P. 333 
aeruginosa infection. We demonstrated that surgical and N95 masks both significantly reduce 334 
the potential for bioaerosol dispersal with >90% reduction in the mean total CFUs. Previous 335 
evidence suggested that impaction of microbe-laden droplets directly onto an obstruction 336 
such as a hand or surgical mask during coughing limits the formation of airborne droplet 337 
nuclei (36); our findings support this suggestion. Likewise, an earlier study also found that 338 
surgical and N95 masks were equally effective in interrupting aerosol transmission of 339 
influenza in nine patients (37). A different study considered the impact of cough etiquette 340 
strategies (including the hand, a tissue, an arm) on preventing cough aerosols in healthy 341 
volunteers (38). Similar to our findings, they reported that the expelled cough aerosol was not 342 
completely blocked by cough etiquette, therefore posing a potential risk for airborne 343 
transmission (38). Importantly, the majority of viable aerosol detected during uncovered 344 
coughing in the current study was in the respirable size range (<4.7um) and this was not 345 
significantly different for the cough etiquette maneuver.  346 
Our study also demonstrates that talking is a low infectious-aerosol producing activity, 347 
potentially indicating that the implementation of mask policies for people with CF within the 348 
hospital should especially target relevant high risk clinical settings. During times of known 349 
high aerosol producing activities (performing spirometry and airway clearance) in the clinical 350 
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setting when a mask is not be feasible, then other considerations such as high air exchange 351 
rates, negative pressure rooms and/or adequate washout time periods between patients in 352 
individual rooms is important.  353 
Although short mask wear duration was overall well tolerated by people with CF, it was 354 
perceived as being less comfortable when compared with no mask for the participant, 355 
particularly the N95 mask where additional outward protection was not observed. This may 356 
be an important factor when considering adherence to correct wearing technique, especially 357 
over extended periods. In healthy subjects and healthcare professionals, the use of face masks 358 
has been associated with increased breathing resistance (39), headaches (40), and physical 359 
discomfort (41, 42), and tolerability lessens with increased duration of wear (43). 360 
Furthermore, the physiological effects and comfort of mask wear amongst people with 361 
respiratory conditions has not been studied extensively and may have adverse impact. One 362 
study that compared surgical and N95 mask efficacy in patients with confirmed influenza 363 
reported that one participant (from a cohort of 10) was unable to complete the short protocol 364 
due to respiratory distress (37). However, Dharmadhikari and colleagues investigated the 365 
clinical efficacy of surgical masks over extended periods in patients with multi-drug resistant 366 
tuberculosis and demonstrated a 56% reduction in transmission risk. Patients wore surgical 367 
masks for up to 12-hours duration, with permitted interruptions for meals and medication, 368 
although it was reported that patients with respiratory distress were not enrolled into the study 369 
and incentives were used to encourage adherence (44). The tolerability of mask wear in 370 
people with respiratory infection and lung disease is an area that requires further 371 
investigation. 372 
High rates of mask interference by the wearer have been reported in people with CF in the 373 
outpatient setting (34). In our study, the participants were unable to touch or readjust the 374 
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masks during the testing period, as the arms were positioned outside of the tunnel. However, 375 
mask movement and slippage during the coughing maneuvers were observed for some 376 
participants. In fact, it was noted that three of the four participants who had detectable P. 377 
aeruginosa CFUs in the N95 mask cough maneuver experienced mask movement, which 378 
may have led to an ineffective facial seal and contributed to the release of viable aerosol.   379 
The participants in this study comprised an adult cohort with moderate to severe lung disease.  380 
Based on earlier data demonstrating a strong correlation between P. aeruginosa sputum 381 
density and cough aerosol concentration (18, 20), sputum-producing participants were 382 
enrolled as a robust means of assessing mask efficacy within the clinical setting. Our results, 383 
nevertheless, highlight the need for additional studies to determine the role and effectiveness 384 
of masks in CF pediatric populations, or for those with preserved lung function and/or those 385 
who rarely expectorate sputum. Despite this, there are some important caveats to consider: i) 386 
one participant in the current study did not produce a sputum sample and importantly, was 387 
one of the six participants who did not culture P. aeruginosa in their cough aerosol. However, 388 
our earlier data demonstrates non-productive patients can produce viable aerosols (18, 20); ii) 389 
quantitative sputum microbiology is not routinely performed in most CF Centers serviced by 390 
clinical microbiology laboratories; iii) other clinical parameters do not predict viable aerosol 391 
production (18, 20) and iv) the infective inoculum of P. aeruginosa (or other CF pathogens) 392 
is not known and therefore we cannot estimate the extent of infection risk for an individual 393 
following single (or for that matter multiple) exposure episodes to cough aerosols. Taken 394 
together, we suggest that a universal mask wearing approach across both adult and pediatric 395 
CF Centers should be strongly considered to mitigate the risk of person-to-person spread of 396 
CF pathogens. 397 
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Limitations of our study include that the application and check of mask fit by a health care 398 
professional and the short mask wearing duration of less than 10-minutes may not reflect the 399 
typical application in a clinical setting; therefore the study may overestimate the protective 400 
effect of face masks. Furthermore, the cough etiquette technique adopted by participants 401 
differed widely, which may impact the results but does allow a more real-world situation. The 402 
culture media used in the Andersen Cascade Impactors and incubation conditions were 403 
selective for non-fastidious, aerobic gram-negative bacteria and did not allow the 404 
investigation of cough aerosol viability of other CF pathogens such as H. influenzae, 405 
Staphylococcus aureus and non-tuberculous mycobacteria. Whilst we focused specifically on 406 
P. aeruginosa in this study, our earlier work has demonstrated similar findings of viable 407 
aerosols of common CF pathogens (18, 20), thus it is likely that the effectiveness of masks 408 
would generalize to other bacteria in people with CF. Finally, compared to the clinically 409 
stable patients, we observed a greater proportion of participants receiving intravenous 410 
antibiotics for pulmonary exacerbations that were low viable aerosol producers. However, the 411 
current study was not powered to examine the impact of clinical status (clinical stability 412 
versus pulmonary exacerbation) and antimicrobial therapies on viable aerosol production. 413 
Further studies are required to address this clinically important question.  414 
In conclusion, masks are a simple and relatively inexpensive method to effectively interrupt 415 
aerosol dispersal of P. aeruginosa in droplet nuclei generated during coughing in people with 416 
CF, with the surgical mask providing enhanced wearer comfort. These data support the USA 417 
CFF Infection Prevention and Control Guidelines for individuals with CF to wear a surgical 418 
mask to reduce environmental contamination and potential viable aerosol spread associated 419 
with coughing in communal areas of health facilities (21). Cough etiquette reduces viable 420 
bacterial aerosols, but not to the same extent as masks. Future studies will assess whether 421 
16 
   
mask application by the wearer and a longer duration of mask wear in a CF cohort impacts 422 
wearer tolerability and mask effectiveness. 423 
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Figure 1. Results of the uncovered cough (reference) maneuver 431 
 432 
 433 
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Table 1. Baseline demographic and clinical characteristics of the study participants  434 
Participant Characteristics 
 
 
 
Participants categorized according to viable Pseudomonas aeruginosa 
aerosol CFUs in the uncovered cough (reference) maneuver 
All participants < 10 CFUs ≥ 10 CFUs p value* 
(n=25)                 (n=11)                 (n=14) 
Age, years, mean (SD) 
 31.3 (7.8) 32.4 (7.0) 30.4 (8.5) 0.53 
Sex, male, n (%) 
 15 (60.0) 6 (54.5) 9 (64.3) 0.70 
BMI, mean (SD) 
 22.1 (2.8) 21.8 (3.1) 22.3 (2.7) 0.70 
FEV1 % predicted, mean (SD) 
 50.7 (17.4) 52.6 (15.8) 49.2 (19.1) 0.64 
IV antibiotics administered in previous 7 days, n (%) 
 11 (44.0) 7 (63.6) 4 (28.6) 0.12 
Pseudomonas aeruginosa CFUs/mL x 107 in sputum, 
mean (95% CI) † ‡ 6.3 (2.6 - 15.0) 2.0 (0.4  - 10.0) 14 (5.9 - 35.0)  
 435 
*Pairwise comparison between participants with <10 (including nil) and ≥10 viable P. aeruginosa aerosol CFUs 436 
†A sputum sample was provided by 24/25 participants 437 
‡Value is geometric mean 438 
Definition of abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 sec; IV, intravenous; CFU, colony forming unit; CI, 439 
confidence interval 440 
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Table 2. Number of participants with detectable aerosol P. aeruginosa colony forming unit (CFU) counts across each study maneuver* 441 
Maneuver 
 
Participants with 
detectable 
P. aeruginosa CFUs, 
n (%) 
Stratification of participants with detectable  
P. aeruginosa CFUs into high and low viable  
aerosol production   
           ˂10*                                               ≥10* 
Uncovered coughing (Reference) 
 
19 / 25 (76.0) 5 / 5 14 / 14 
Talking† 
 
1 / 24 (4.2) 0 / 5 1 / 13 
Talking wearing a surgical mask† 
 
1 / 24 (4.2) 0 / 5 1 / 13 
Coughing wearing a surgical mask 
 
2 / 25 (8.0) 0 / 5 2 / 14 
Coughing wearing an N95 mask‡ 
 
4 / 24 (16.7) 1 / 5 3 / 14 
Cough etiquette 
 
13 / 25 (52.0) 2 / 5 11 / 14 
 442 
*Participants were stratified according to a pre-defined definition of high (≥ 10 CFU) and low (<10 CFU) viable aerosol production of detectable 443 
P. aeruginosa CFU during the uncovered cough maneuver.  444 
†One participant did not complete the maneuver (insufficient culture media available) 445 
‡One participant did not complete the maneuver (due to adverse event) 446 
Definition of abbreviations: CFUs, colony forming units 447 
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Table 3. Pseudomonas aeruginosa total colony-forming unit (CFU) counts for each of the 448 
maneuvers compared to uncovered coughing (reference) for the high viable aerosol producers 449 
(n=14) 450 
 451 
 452 
*One participant did not complete the maneuver (insufficient culture media available) 453 
†One participant did not complete the maneuver (due to adverse event) 454 
Definition of abbreviations: CI, confidence interval; CFUs, colony forming units 455 
456 
Maneuver Log10 P. aeruginosa CFUs 
 mean (95% CI)  
p value 
Uncovered coughing (reference) 
 
1.66 (1.41-1.91) - 
Talking* 
 
0.02 (0.00-0.07) <0.001 
Talking wearing a surgical mask* 
 
0.02 (0.00-0.07) <0.001 
Coughing wearing a surgical mask 
 
0.11 (0.00-0.32) <0.001 
Coughing wearing an N95 mask† 
 
0.13 (0.00-0.30) <0.001 
Cough etiquette 
 
0.90 (0.50-1.30) <0.001 
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Table 4. A matched pairs comparison of the comfort levels during cough maneuvers while 457 
wearing the surgical mask and the N95 mask (n=24) * 458 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
* Comfort level categories: a) very poor, b) poor, c) sufficient, d) good, e) very good. A low 468 
number of responses were obtained in the a) very poor and e) very good categories; therefore, 469 
for the analysis, the categories of a) very poor and b) poor were combined (“poor”), as were 470 
the categories of d) good and e) very good (“good”).   471 
The boxed area represents participants (n=9) who reported no preference for the comfort of 472 
the surgical mask or the N95 mask. Numbers to the right of the boxed area represent 473 
participants (n=2) who provided a higher comfort rating to the N95 mask and those to the left 474 
represent participants (n=13) who provided a higher comfort rating to the surgical mask. 475 
                    N95 mask 
    
    
    
    
    
 Su
rgi
cal
 m
ask
 
 Poor Sufficient Good Total 
Poor  3 1 0 4 
Sufficient 11 2 1 14 
Good  0 2 4 6 
Total 14 5 5 24 
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